Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

National Cancer Institute (NCI)

Status and phase: Completed; Phase 2

Conditions: Head and Neck Cancer; Oral Leukoplakia

Treatments: Drug: pioglitazone hydrochloride

Study type: Interventional

Funder types: NIH

Identifiers

NCT00099021

0109 M 07254 (Other Identifier)

N01CN15000 (Other Identifier)

CDR0000393562

NCI-2009-00862 (Registry Identifier)

N01-CN-15000 (Other Identifier)

2001LS068

Details and patient eligibility

About

This phase II trial studies how well pioglitazone hydrochloride works in preventing head and neck cancer in patients who have oral leukoplakia. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of pioglitazone hydrochloride may be effective in preventing head and neck cancer.

Full description

PRIMARY OBJECTIVES:

I. Determine whether pioglitazone (pioglitazone hydrochloride) reverses leukoplakia in patients with hyperplastic or dysplastic oral cavity or oropharyngeal leukoplakia.

SECONDARY OBJECTIVES:

I. Determine the safety and tolerability of this drug in these patients.

OUTLINE: This is an open-label study.

Patients receive pioglitazone hydrochloride orally (PO) once daily (QD) for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.

Patients are followed up at 4, 8, 12, and 16 weeks.

Enrollment: 21 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Criteria:

• ECOG 0-2
• Diagnosis of oral cavity or oropharyngeal leukoplakia meeting 1 of the following criteria:
• Biopsy-proven hyperplasia in high-risk anatomic areas (e.g., floor of the mouth, mobile tongue, oropharynx, or in any erythroplakia lesion)
• Mild, moderate, or severe dysplasia at any site of the oral cavity or oropharynx within the lesion
• Measurable lesion that is clinically characterized by leukoplakia, erythroplakia, or erythroleukoplakia
• Able to be assessed by bi-directional measurements
• Life expectancy: More than 3 months
• Hemoglobin >= lower limit of normal for males and post-menopausal females OR
• Hemoglobin >= 11 g/dL for premenopausal females
• WBC > 3,000/mm^3
• Hepatic: Bilirubin < 1.5 times upper limit of normal (ULN); AST and ALT < 1.5 times ULN
• Renal: BUN < 1.5 times ULN; Creatinine < 1.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception
• No contraindication to thiazolidinediones
• No allergy to pioglitazone or other thiazolidinediones
• No serious oral infection
• No invasive carcinoma within the past 60 months except nonmelanoma skin cancer or carcinoma in situ of the cervix
• No concurrent malignancy
• More than 3 months since prior biologic or immunologic therapy
• No concurrent insulin for diabetes
• No prior radiotherapy to the oral cavity
• More than 3 months since prior chemopreventative agents
• More than 3 months since prior experimental therapy
• More than 3 months since prior megadose vitamins or alternative therapy
• No prior thiazolidinediones
• No prior participation in this study
• No concurrent pharmacologic treatment for diabetes
• Concurrent chronic use of non-steroidal anti-inflammatory drugs allowed
• Platelet count > 125,000/mm^3
• Index lesion must be located in an anatomic site accessible by punch biopsy

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

Prevention (pioglitazone hydrochloride)

Experimental group

Description:

Patients receive pioglitazone hydrochloride PO QD for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.

Treatment:

Drug: pioglitazone hydrochloride